Trial
NCT04786600
A Phase II Randomized Therapeutic Optimization Trial for Subjects With Refractory Metastatic Colorectal Cancer Using ctDNA: Rapid 1 Trial
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Florida
Collaborators
Natera, Inc.
Condition
Metastatic Colorectal Cancer
Intervention
Signatera ctDNA assay
Why stopped
slow accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-07-01